Does Rallies show 13F holders for ICCM?

Yes. Rallies tracks hedge fund and 13F ownership data for ICCM, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ICCM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ICCM. It does not provide personalized investment advice.

ICCM (IceCure Medical Ltd. Ordinary Shares) Stock Analysis - Hedge Fund Holdings

IceCure Medical Ltd. Ordinary Shares (ICCM) is a publicly traded Healthcare sector company. As of May 19, 2026, ICCM trades at $0.22 with a market cap of $18.67M and a P/E ratio of 0.00. ICCM moved -0.32% today. Year to date, ICCM is -65.08%; over the trailing twelve months it is -78.85%. Its 52-week range spans $0.22 to $1.66. Analyst consensus is buy with an average price target of $1.00. Rallies surfaces ICCM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ICCM stock?

Hedge funds tracked by Rallies that own ICCM include Citadel Advisors, Two Sigma, Two Sigma, and Renaissance Technologies. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for IceCure Medical Ltd. Ordinary Shares.

ICCM Key Metrics

Key financial metrics for ICCM
Metric	Value
Price	$0.22
Market Cap	$18.67M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$1.66
52-Week Low	$0.22
Volume	1.10M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding ICCM

Citadel Advisors holds 169.51K shares of ICCM, changed +231.65% as of Jun 30, 2024.
Two Sigma holds 18.52K shares of ICCM, changed -12.84% as of Sep 30, 2024.
Two Sigma holds 17.00K shares of ICCM, changed +2.62% as of Dec 31, 2024.
Renaissance Technologies holds 10.90K shares of ICCM, changed -83.58% as of Dec 31, 2024.

Latest ICCM News

IceCure ProSense® Achieves 89.4% Renal RFR and 100% Breast Cryoablation Success — May 19, 2026
IceCure Secures 180-Day Nasdaq Extension to Meet $1.00 Bid Requirement — May 13, 2026
IceCure Q1 2026 Revenue Up 26% to $911K, U.S. Sales Jump 31% — May 12, 2026
IceCure Sees Over 30% Q1 2026 Revenue Growth for ProSense Cryoablation — May 5, 2026
IceCure Medical Secures $4 Million Financing with 16M Warrants — Mar 26, 2026

ICCM Analyst Consensus

2 analysts cover ICCM: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $1.00.

Common questions about ICCM

Who owns ICCM stock?: Hedge funds tracked by Rallies that own ICCM include Citadel Advisors, Two Sigma, Two Sigma, and Renaissance Technologies. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for IceCure Medical Ltd. Ordinary Shares.
Does Rallies show 13F holders for ICCM?: Yes. Rallies tracks hedge fund and 13F ownership data for ICCM, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ICCM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ICCM. It does not provide personalized investment advice.